Indications for Rituximab

Rituximab is a prescription drug. Rituximab is a type of targeted cancer drug called a monoclonal antibody. Monoclonal antibodies target proteins on the surface of cancer cells. Rituximab targets a protein called CD20. CD20is found in white blood cells called B cells. Rituximab works by attaching itself to all the CD20 proteins it finds.

Rituximab(Rituximab) is indicated as a monotherapy for patients with relapsed or refractory, low-grade or follicular CD20positiveB cell non-Hodgkin lymphoma. It is suitable for patients with previously untreated follicular CD20positive B cells NHL combined with first-line chemotherapy, as well as patients who have achieved complete or partial response to rituximab products combined with chemotherapy, as single-agent maintenance therapy. It is suitable for monotherapy in patients with non-progressive (including stable disease), low-grade, CD20positive B cell NHL after first-line cyclophosphamide, vincristine and prednisone (CVP) chemotherapy. It is suitable for combined treatment with CHOP or other anthracycline-based chemotherapy regimens for patients with previously untreated diffuse large B, CD20positive NHL. Rituximab is indicated in combination with fludarabine and cyclophosphamide (FC) for the treatment of previously untreated and previously treated adult patients with CD20-positive CLL. Rituximab in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have not responded to treatment with one or more TNF antagonists. Rituximab is used in combination with corticosteroids to treat adult patients with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA). If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.